-transparent.png){kind=logo}
Parenteral (i.v.) injection of growth hormone-releasing factor (GRF) increases the height of the 3,4-dihydroxyphenylacetic acid oxidation peak (peak 2) but does not change 5-hydroxyindole extracellular content (peak 3) in the arcuate nucleus of the hypothalamus, both peaks being recorded by the differential pulse voltammetry technique using a single specifically pretreated monopyrolytic carbon fibre electrode. Conversely, no significant changes are observed in the peak 2 and peak 3 heights recorded in the medial or in the lateral nucleus of the hypothalamus. These data suggest a specific interaction between GRF and the dopaminergic system.
Related Publications
F Crespi, and
J Paret, and
P E Keane, and
M Morre, and
F X Coude, and
R Roncucci
January 1986,
Experimental brain research,
F Crespi, and
J Paret, and
P E Keane, and
M Morre, and
F X Coude, and
R Roncucci
November 1988,
Neuroendocrinology,
F Crespi, and
J Paret, and
P E Keane, and
M Morre, and
F X Coude, and
R Roncucci
April 1985,
European journal of pharmacology,
F Crespi, and
J Paret, and
P E Keane, and
M Morre, and
F X Coude, and
R Roncucci
August 2006,
Journal of Nippon Medical School = Nippon Ika Daigaku zasshi,
F Crespi, and
J Paret, and
P E Keane, and
M Morre, and
F X Coude, and
R Roncucci
March 1984,
Neuropeptides,
F Crespi, and
J Paret, and
P E Keane, and
M Morre, and
F X Coude, and
R Roncucci
March 2003,
Journal of neuroendocrinology,
F Crespi, and
J Paret, and
P E Keane, and
M Morre, and
F X Coude, and
R Roncucci
January 1986,
Neuroendocrinology,
F Crespi, and
J Paret, and
P E Keane, and
M Morre, and
F X Coude, and
R Roncucci
July 2002,
The Journal of neuroscience : the official journal of the Society for Neuroscience,
F Crespi, and
J Paret, and
P E Keane, and
M Morre, and
F X Coude, and
R Roncucci
July 1992,
Neuroendocrinology,
F Crespi, and
J Paret, and
P E Keane, and
M Morre, and
F X Coude, and
R Roncucci
October 1985,
Brain research,
